⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12243171 | 0.82 | — | — | |
| SCHEMBL8325180 | 0.78 | RAB9A (0.34) | — | |
| SCHEMBL25628682 | 0.70 | HSD11B1 (0.32) | — | |
| SCHEMBL12048542 | 0.70 | — | — | |
| SCHEMBL10129241 | 0.70 | RAB9A (0.34) | — | |
| SCHEMBL22313118 | 0.70 | — | — | |
| SCHEMBL23345349 | 0.69 | CYP1A2 (0.43) | — | |
| SCHEMBL791425 | 0.68 | — | — | |
| SCHEMBL24009008 | 0.63 | — | — | |
| SCHEMBL209495 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024020380-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2023018809-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| EP-3601254-B1 | QUINOXALINE AND PYRIDOPYRAZINE DERIVATIVES AS PI3K-BETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-25 | — | — | EP | disclosed |
| US-20210395238-A1 | NADPH OXIDASE 4 INHIBITORS | ACTELTION PHARMACEUTICALS LTD (CH) | 2021-12-23 | — | — | US | disclosed |
| EP-3359533-B1 | QUINOXALINE AND PYRIDOPYRAZINE DERIVATIVES AS PI3KBETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-17 | — | — | EP | disclosed |
| US-11136317-B2 | NADPH oxidase 4 inhibitors | ACTELION PHARMACEUTICALS LTD (CH) | 2021-10-05 | — | — | US | disclosed |
| US-11130751-B2 | Quinoxaline and pyridopyrazine derivatives as PI3K-beta inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-28 | — | — | US | disclosed |
| EP-3638670-B1 | SUBSTITUTED PYRROLOPYRIDINE-DERIVATIVES AS MAP4K1 MODULATORS FOR THE TREATMENT OF CANCER DISEASES | Bayer Pharma AG (DE) | 2021-07-21 | — | — | EP | disclosed |
| EP-3472160-B1 | BICYCLIC PYRIDINE, PYRAZINE, AND PYRIMIDINE DERIVATIVES AS PI3K BETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-02-24 | — | — | EP | disclosed |
| US-10894793-B2 | Bicyclic pyridine, pyrazine, and pyrimidine derivatives as PI3K beta inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-01-19 | — | — | US | disclosed |
| US-7939533-B2 | Dual NK1/NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-7939533-B2 | Dual NK1/NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-7928122-B2 | Modulators of cellular adhesion | SARCODE CORPORATION (US) | 2011-04-19 | — | — | US | disclosed |
| US-7745460-B2 | Modulators of cellular adhesion | SARCODE CORPORATION (US) | 2010-06-29 | — | — | US | disclosed |
| US-20100093693-A1 | MODULATORS OF CELLULAR ADHESION | BAUSCH + LOMB IRELAND LIMITED (IE) | 2010-04-15 | — | — | US | disclosed |
| US-20090137806-A1 | DUAL NK1/NK3 RECEPTOR ANTAGONISTS | HOFFMANN TORSTEN | 2009-05-28 | — | — | US | disclosed |
| US-20090137806-A1 | DUAL NK1/NK3 RECEPTOR ANTAGONISTS | HOFFMANN TORSTEN | 2009-05-28 | — | — | US | disclosed |
| US-7314938-B2 | Immune and/or inflammatory disorders; autoimmune disorders; disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1); antagonize CD11/CD18 receptors associated with leukocytes. | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| EP-1643998-B1 | DUAL NK1/NK3 ANTAGONISTS FOR TREATING SCHIZOPHRENIA | HOFFMANN LA ROCHE (CH) | 2007-08-29 | — | — | EP | disclosed |
| WO-2005002577-A1 | DUAL NK1/NK3 ANTAGONISTS FOR TREATING SCHIZOPHRENIA | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-13 | — | — | WO | disclosed |